Beyond Fungisome, other products could be considered as generics of liposomal amphotericin B. Bioequivalence to AmBisome has to be established then through adapted processes.
4 Before any generic product can be used for visceral leishmaniasis, liposomal ampho tericin B suppliers should submit their products to the WHO Prequalification Programme, the remit of which has been expanded to liposomal ampho tericin B, 5 to determine which medicines are quality-assured and bioequivalent to AmBisome. This is the only safeguard to avoid exposing visceral leishmaniasis patients to products with an unassessed safety and effi cacy profi le. 
